About
Biologics
Areas of Focus
Categories
Biologics & Biopharmaceutical
Clinical Trials (48)
View allTotal Trials
48
As Lead Sponsor
29
As Collaborator
19
Total Enrollment
13,165
By Phase
PHASE2: 13PHASE3: 11NA: 7PHASE1/PHASE2: 3PHASE1: 6PHASE4: 4PHASE2/PHASE3: 1
By Status
COMPLETED: 28TERMINATED: 8RECRUITING: 6UNKNOWN: 3WITHDRAWN: 2NOT_YET_RECRUITING: 1
Clinical Trials Pipeline48 trials
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Phase 1/2
Phase 2/3
N/A
2002
2003
2004
2005
2006
2007
2008
2009
2010
2011
2012
2013
2014
2015
2016
2017
2018
2019
2020
2021
2022
2023
2024
2025
2026
2027
2028
2029
2030
2031
2032
2033
2034
2035
2036
Today
Hover over trial bars to see details
Recent Trials
NCT07159451Collaborator
A Short-term Preoperative, Evaluating Activity and Safety of Elacestrant Monotherapy as Compared to Elacestrant + Ovarian Function Suppression (LHRH Agonist) in Premenopausal Patients With Stage I-II ER+/HER2- Breast Cancer
PHASE2Not yet recruiting
140 participants
Started: Sep 23, 2025 · Completed: Mar 23, 2027
NCT06991946Collaborator
Patient-Centric Study to Assess the Impact of Genomic Profiling on the Treatment of Patients With Metastatic Breast Cancer in Spain
N/ARecruiting
300 participants
Started: May 20, 2025 · Completed: May 20, 2030
NCT06828848Lead Sponsor
A Study to Assess How Vaborem® is Taking up in the Body and Tolerated in Paediatric Patients With Gram Negative Infections, Including But Not Restricted to Complicated Urinary Tract Infections
PHASE2Recruiting
44 participants
Started: Feb 18, 2025 · Completed: Jul 31, 2026
NCT06534437Collaborator
MEN1703 (SEL24) to Treat Relapsed or Refractory Aggressive B-cell Non-Hodgkin Lymphoma (JASPIS-01)
PHASE2Recruiting
178 participants
Started: Dec 5, 2024 · Completed: Dec 31, 2026
NCT05512364Collaborator
Elacestrant for Treating ER+/HER2- Breast Cancer Patients With ctDNA Relapse (TREAT ctDNA)
PHASE3Recruiting
220 participants
Started: Dec 15, 2023 · Completed: Nov 1, 2035
Locations (1)
Headquarters
Florence, Italy
Map
Loading map...